Evidence map›Paper›PMID 40717099›Full record

ArticleJournal of medical case reports2025

Critical illness in immunocompromised patients: insights into relapse or persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): case series report.

Olga H Hernández-Ortiz, Juan Felipe Llano, Ana Milena Sánchez, Fabian Jaimes, A Melissa Moreno, Laura S Perez-Restrepo, Jaime Usuga, Erwin Camacho, Jorge E Osorio, Juan Pablo Hernández-Ortiz

Abstract readCase Reports
In one paragraph

Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Olga H Hernández-OrtizGlobal Health Institute (GHI) One Health Colombia and One Health Genomic Laboratory, Universidad Nacional de Colombia, Medellín, Colombia.
Juan Felipe LlanoClínica Medellín-Grupo Quirónsalud, Medellín, Colombia.
Ana Milena SánchezHospital Pablo Tobón Uribe, Universidad Pontificia Bolivariana, Medellín, Colombia.
Fabian JaimesUniversidad de Antioquia, Medellín, Colombia.
A Melissa MorenoGlobal Health Institute (GHI) One Health Colombia and One Health Genomic Laboratory, Universidad Nacional de Colombia, Medellín, Colombia.
Laura S Perez-RestrepoGlobal Health Institute (GHI) One Health Colombia and One Health Genomic Laboratory, Universidad Nacional de Colombia, Medellín, Colombia.
Jaime UsugaGlobal Health Institute (GHI) One Health Colombia and One Health Genomic Laboratory, Universidad Nacional de Colombia, Medellín, Colombia.
Erwin CamachoResearch and Development Department, VaxThera, Medellin, Colombia.
Jorge E OsorioGlobal Health Institute, University of Wisconsin-Madison, Madison, WI, United States. jorge.osorio@wisc.edu.
Juan Pablo Hernández-OrtizGlobal Health Institute (GHI) One Health Colombia and One Health Genomic Laboratory, Universidad Nacional de Colombia, Medellín, Colombia. jphernandezo@unal.edu.co.ORCID http://orcid.org/0000-0003-0404-9947

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUpon the pandemic transitioning into a new phase, research into the immune pathophysiology of severe and critical coronavirus disease 2019 has become increasingly crucial. Such studies are pivotal in shaping advanced treatment strategies and driving the development of innovative therapeutics, including more effective vaccines targeting the virus. High-risk comorbidities and pre-existing immunocompromised states have been identified as significant factors contributing to increased susceptibility to severe coronavirus disease 2019. Moreover, cases of severe infections, particularly those characterized by relapses or viral persistence, provide invaluable insights into the evolving behavior and dynamics of this pathogen. CASES SERIES PRESENTATION: We report three cases involving mixed-race Colombian female patients aged 58, 35, and 63 years who experienced multiple episodes of coronavirus disease 2019 infection, with the most recent episode progressing to critical illness. These cases were characterized by relapses or persistent infections, and genomic analyses consistently identified the Omicron severe acute respiratory syndrome coronavirus 2 lineage as the causative variant. Notably, individuals with underlying immunosuppressive conditions developed severe acute respiratory syndrome coronavirus 2 infections that were more severe, leading to fatal outcomes that included acute respiratory distress syndrome, multiorgan dysfunction, and death. In contrast, one vaccinated patient with significant comorbidities exhibited persistent critical coronavirus disease 2019 but responded positively to treatment with tocilizumab.

conclusionsThe key takeaway is the critical need for continued investigation into coronavirus disease 2019 among individuals with high-risk comorbidities and those undergoing immunosuppressive therapy. Recurrent episodes of infection, including cases marked by relapses or persistent viral presence in these populations, create conditions conducive to viral replication and adaptation. Such environments may potentially act as breeding grounds for the emergence of significant new viral mutations.

Indexed as

COVID-19Immunocompromised HostSARS-CoV-2AdultAntibodies, Monoclonal, HumanizedColombiaCritical IllnessFatal OutcomeFemaleHumansMiddle AgedRecurrenceAntibodies, Monoclonal, HumanizedtocilizumabCase series reportCOVID-19Critical COVID-19PersistentRelapse

Identifiers

PMID40717099
PMCPMC12302890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.